Verified peer comparison

MRK vs NVO

Merck & Co., Inc. compared with Novo Nordisk A/S. This page compares both source-verified company profiles and does not introduce an unverified price target.

MRK

Merck & Co., Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

NVO

Novo Nordisk A/S

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

MRK: Pharmaceuticals

NVO: Pharmaceuticals

Upside lens

MRK: Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products. A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

NVO: Greater diagnosis, treatment capacity and reimbursement can expand the addressable obesity population. Fill-finish and active-ingredient investments can improve supply and support broader launches. Oral and combination therapies can extend leadership across obesity, diabetes and related conditions.

Risk lens

MRK: Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks. Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches. Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.

NVO: Rival efficacy, supply and pricing can pressure share and growth across diabetes and obesity. Payer restrictions, government negotiation and affordability concerns can reduce realized economics. Quality findings or delays in complex capacity projects could constrain supply during rapid demand growth.